Fremanezumab (TEV-48125) is a humanised monoclonal antibody targeting CGRP, capable of neutralising human (IC50=7.94 nM), mouse (IC50=19.6 nM) and rat CGRP, and is indicated for the prevention of migraine. Fremanezumab inhibits CGRPs vasodilatory effects in the basilar artery constriction segment and suppresses activation of A-delta and high-threshold (HT) neurons in the meningeal nociceptive system triggered by cortical spreading depression (CSD) in rats. In vitro, Fremanezumab counteracts CGRPs immunosuppressive effects on microglia and lymphocytes.
Purity:
95.00%
CAS Number:
[1655501-53-3]
Target:
CGRP Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
